Beam Therapeutics Inc
Fermé
SecteurSoins de santé
29.06 -1.29
Résumé
Variation du prix de l'action
24h
Min
28.68
Max
29.09
Revenu | -339M -94M |
|---|---|
Ventes | -82M 32M |
BPA | -0.91 |
Marge bénéficiaire | -297.177 |
Employés | 522 |
EBITDA | -362M -102M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +77.68% upside |
Prochains Résultats | 4 août 2026 |
|---|
Capitalisation Boursière | -41M 3B |
|---|---|
Ouverture précédente | 30.35 |
Clôture précédente | 29.06 |
Sentiment de l'Actualité
By Acuity
50%
50%
146 / 342 Classement par Healthcare
Beam Therapeutics Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.